Looking at the world, there are a lot of big pharmaceutical companies, but there are fewer players like Roche who can break the game. Roche has risen from the fifth place in 2013 to the third place in the world pharmaceutical company's revenue ranking in 2014. Since then, it has been in the top three for the fourth consecutive year with Pfizer and Novartis. As the world's largest health care company, the Roche fleet is driven by both the pharmaceutical and diagnostic engines. In the past, two carriages could drive pharmaceutical companies forward, but in the digital future, as more and more Internet companies play a role as a platform, consumers will be the center to meet their needs. Pharmaceutical companies need to build their own ecological networks through digital transformation. Michele Pedrocchi, director of global strategy and business development at Roche Diagnostics, said frankly: "We have a lot to learn, but we are working on it and speeding up quickly. Ultimately, personalized medicine in the digital age will lead to better medical decisions. We will increasingly conduct preventive analysis and treatment. In the past, our relationship with our partners was a one-to-one, one-way partnership, but now we have to be many in a standardized and flexible ecosystem. Partners come together to move towards the era of precision medicine and personalized medicine." The wind started at the end of Qingping, and Roche began to evolve from a big tree to a forest road, which extended the digital tentacles. The arterial network (micro-signal: vcbeat) analyzes its digital innovation logic by combing Roche dynamics. Roche: R&D high investment, acquisition of low price copy Roche's revenue for 2017 was $38.791 billion. Achieved a 5% increase in revenue in the pharmaceutical sector, such a strong growth, in the Roche's 2017 earnings report attributed the growth of several new drugs. It can be seen from the development of Roche that Roche, as a younger pharmaceutical company, succeeded in PK off the drug companies such as Shamodong, Sanofi, Johnson and Johnson, and rewritten the layout of pharmaceutical companies. In the past 20 years, Arterial Network has found that the three carriages driving Roche's growth are innovation, acquisition and advanced research and development. First, research and development Roche's investment in R&D is arguably the most profitable company. This fine tradition has been established since Roche's revenue has not yet entered the top three pharmaceutical companies. It can be seen from the data that Roche's R&D investment has always been the first and has maintained a certain growth rate. Three of Roche's R&D team have won the Nobel Prize. Although maintaining high R&D investment has now proved to be a good thing for the predecessors to plant trees and then enjoy the cool. However, for the pharmaceutical industry, such a huge investment in the development of new drugs, in fact, it is likely to be high-risk and low-reward, but Roche has achieved high investment and high returns. Not to mention that Roche successfully used the development of new product lines to resolve patent lands in the 1970s and 2000s. This year, Roche successfully developed drugs for the treatment of autism and Alzheimer's disease. Roche's oral new drug balovaptan is considered a breakthrough therapy for autism through FDA certification. This year, Roche conducted two large phase III clinical studies of Alzheimer's disease. In the same period, Pfizer announced the abandonment of development projects for Alzheimer's disease and Parkinson's disease. Second, mergers and acquisitions Mergers and acquisitions can be said to be the best use in the pharmaceutical industry, what to buy if you need anything. Roche has repeatedly purchased potential companies with the precise vision of the president to help Roche out of the bottom and stand firm in the market. The most classic one is the acquisition of Genentech. In 1986, nearly 60% of the biotech company Genentech was acquired at a low price of $1.537 billion. With Genentech's headwinds, Genentech was not optimistic about biopharmaceuticals in the 1990s that brought a lot of revenue to Roche. Of course, this move is still very useful in digital innovation. Roche still uses acquisition methods to integrate data tools from various sources, establish a sound health care ecological network, and provide new choices for health care workers. Laboratories, regulators, and researchers are included in the collaborative network. Third, anticipate the next generation of drug development direction Roche's greatest success lies in its advanced business layout and its ability to step into the next generation of drug development. After World War II, Roche made a sedative and hypnotic drug, but in 1965, the then president, Adolf Jann, gradually led Roche to divest from the two sedative hypnotic drugs, increasing diversification and expanding the business to the entire healthcare sector. It was also in the 1960s that Roche began to develop the development of biological products and diagnostic products. Later, Roche's three major star monoclonal antibodies accounted for the top three global cancer drug sales, Roche can be said to occupy half of the field of monoclonal antibody. In the future, Roche's core business is still to discover and develop drugs. But as Gregg Talbert, global director of digital and personalized medical collaboration at Roche, said: “We have realized that in the future, developing drugs and discovering drugs must have strong partnerships to take advantage of innovation outside our field.†In the next 20 years, Roche is optimistic about precision medicine and personalized medicine. The concept of Roche's official website is Doing now what patients need next. The medical future of Roche's bet is precision medicine and personalized medicine. There are three reasons for Roche's digital innovation through data: First, precision medical care is the general trend of all parties. The second is to relieve the current difficulties in research and development of new drugs. The third is to take advantage of the existing diagnostic business. Precision medicine and personalized medicine are seen as blueprints for future medical care. Precision medicine is based on individualized medicine. With the rapid advancement of genome sequencing technology and the cross-application of biological information and big data science, the essence of new medical concepts and medical models. Precision medicine is first driven by patient data, rather than doctor-driven in traditional medicine. Precision medicine can usher in great development and benefit from policy promotion. In 2016, US President Barack Obama spent $215 million to launch a precision medical research program with NIH, FDA, and ONC. Second, the United States has also introduced relevant supporting measures. At the end of 2016, the US Congress announced the 21st Century Healing Act, which proposed that Real World Evidence could be used to replace traditional clinical trials to expand indications for accelerating the listing of drugs and medical devices. Let pharmaceutical companies pay more attention to the investment in real world research. In the field of cancer where Roche is now leading the way, the trend of individualization and precision of cancer treatment is on the rise, and cancer treatment currently accounts for about 60% of Roche's total income. Cancer treatment is not limited to the treatment of symptoms. With the development of medicine, the ability to observe the genetic makeup of a human tumor in a relatively fast and low-cost manner is an important direction for cancer treatment. In the United States, about 1.6 million people were diagnosed with cancer in 2016, but no two have the same pathological mechanism. Since 1991, cancer mortality has dropped by about 20%, and the relative survival rate has increased to 68%. . A major change in treatment options was the discovery that tumors are driven by individual genes. Everyone's cancer has a unique set of genetic information. Future cancer drug development should also be developed to achieve precise medication for different groups and even individuals. And how to identify large-scale groups or similar diseases, a large amount of structured data becomes a necessity. Of course, Roche’s $1.9 billion acquisition of a tumor data company like Flatiron is not intended to buy insurance for future medical care. It is to relieve the current difficulties in research and development of new drugs. Mastering medical data can be said to build infrastructure for new drug research and development. Roche's main drugs Rituxan, Herceptin and Avastin expired in the US patents in 2018, 2019, and 2020, respectively. In 2017, due to the competition of generic drugs, Roche's revenue in Europe on its old site fell by 2%. And in the future, many of Roche's best-selling drugs will soon expire. For example, the Herceptin patent is about to expire, which directly leads to a market redistribution of $6 billion. In the 2017 financial report, there were as many as 31 tumor compounds in Roche's Phase III clinical trial. Rao is so anxious about the development of new drugs, but if you don't change the existing clinical trials, it will take an average of ten years for each new drug to be successfully listed. So in order to ensure the growth of key business, Roche urgently needs to use real-world data and analysis to accelerate clinical trials. Oncology big data companies like Flatiron can quickly match patients in clinical trials and accelerate the launch of new drugs based on cost reduction. Michele Pedrocchi, director of global strategy and business development at Roche Diagnostics, said: "In the future, we will use data from various patient characteristics to determine the best combination of treatments to improve the overall medical condition of patients. Although there are still many uncertainties in the digital innovation of pharmaceutical companies, Roche's choice of precision medical care is more important to match the advantages of its own diagnostic business. In 2017, Roche's global diagnostic business achieved a 5% year-on-year increase in sales revenue of 12.1 billion Swiss francs (approximately $12.9 billion). In the era of precision medicine, the diagnostic business will be more promising than the pharmaceutical business. First of all, the diagnostic business can also realize the compression medical cost under the medical insurance control fee and promote the growth of the low-cost business model medical service. According to the statistics of Roche diagnosis, the in vitro diagnosis can affect 60% of the clinical treatment plan, but the cost only accounts for the whole clinical 2% of the cost of treatment. At the same time, this is also a trend that changes with the increase of chronic diseases in the future. In the future medical care, with the development of the Internet of Things, sensors and mobile devices, medical behavior will be integrated into prevention, screening, diagnosis, prognosis, treatment and monitoring. Prevention and prognosis are the neglect of the existing medical system, and it is precisely the link that can greatly improve medical effects and reduce medical costs. The diagnosis plays an important role in continuous health monitoring in early screening. Now, the development of molecular diagnostics and genetic diagnosis also illustrates the development trend of diagnostic business in precision medicine. Data to improve clinical trials and accelerate new drug development At the current stage, the development of new drugs can be said to be the lifeblood of pharmaceutical companies. In the case of Roche, Roche’s main sector revenue increased by 5% last year to 41 million francs. In the annual report, Roche attributed the growth to the newly developed drug Octreus for the treatment of multiple sclerosis MS, and the first PD-L1 inhibitor approved by the FDA for Tecentriq, a new targeted therapy for bladder cancer. If there is no new drug on the market, there is a patented cliff, the tiger, and there are a lot of clinical trials. Pharmaceutical companies will be struggling. The development of new drugs takes an average of more than 10 years. The problems faced by pharmaceutical companies are not only the expiration of patents, but also the emergence of new drugs. New drug development is becoming more and more difficult, and fewer and fewer compounds can be used to develop new drugs. Pfizer revealed in the annual report last year that 13 projects were cut. When the arterial network combed Roche's movements, it was found that there were few AIs in Roche's partners, and Roche valued the data more. In the clinical trial of new drugs, Roche is transforming clinical trials in a digital way, improving the efficiency of clinical trials and accelerating the development of new drugs. Prothena In June 2017, Roche announced a partnership with Prothena to develop a User Monitoring App for Phase II clinical trials. In developing a clinical trial for the treatment of Parkinson's drugs, Roche updated the traditional scale assessment method and designed an APP with a comprehensive evaluation kit that continuously monitors and captures the symptoms of Parkinson's patients. With this smartphone, clinical researchers can no longer need to get the patient's condition every time through inquiry, and can get more sensitive and comprehensive results data than one-time test in a short time. The ultimate goal is to quickly and reliably capture large amounts of data to monitor individual treatment responses and then allow for personalized treatment. This can enhance patient compliance in clinical trials while achieving more accurate drug use. Patient compliance in clinical trials is important to accelerate new drug development. According to Cognizant's report on recruitment forecasts, approximately 80% of clinical trials failed to recruit appropriate patients within the timeframe, and approximately one-third of Phase III clinical trials were terminated due to patient recruitment difficulties. In Roche, in 2017, Roche conducted clinical trials of more than 295,000 patients. Roche hopes to make clinical trials easier and allow patients and clinical researchers to have a higher level of participation. Minimize their inconvenience and the time and effort required. And digital technology can spread centralized clinical trials to patients' homes. This series of ongoing data feedback allows researchers to better identify potential drug combinations. Flatiron Health Roche spent $1.9 billion to acquire Flatiron Health, the largest acquisition of artificial intelligence. What Roche is looking at is the vast amount of real-world data that is integrated behind Flatiron Health. The company has collected more than 30% of cancer patients in the United States, far exceeding other competitors in the field. Roche can use Flatiron Health's data for clinical trial patient matching. Patient matching for cancer therapy is very difficult. Due to the continuous evolution of cancer and the long time-consuming development of new drugs, the time difference between the two directly leads to a very small target patient population in each clinical trial. Although the AI ​​is now called a fast match, AI is useless if no data is available. A large data ecosystem requires a high degree of coordination, standardization and analysis, all of which will depend on the cooperation of healthcare companies and technology partners. Roche CEO said to the acquisition of Flatiron Health: "Flatiron Health's data analysis organization is not only useful for Roche, but also for the oncology research and development of the entire industry." GNS Healthcare Data collected by GNS includes electronic medical records, medical device data, genomics information, medical consumer behavior, and adverse reactions to medications. Use this data to match the patient's health interventions and medications that are best suited to the individual patient. This, in turn, can help medical institutions improve their efficacy in preterm delivery, drug compliance, metabolic syndrome, diabetes, and specialist care for cancer treatment, reducing costs. Roche's subsidiary, Genentech and GNS, reached an agreement to use GNS's AI platform to analyze the efficacy of known therapies in oncology using the GAS AI platform. Roche is piloting the GNS specification to analyze large amounts of proprietary data, such as electronic medical records and next-generation sequencing data. Hope to reveal hidden drivers of cancer progression and drug response in some of the most challenging cancers. The collaboration aims to generate unique insights from an increasing number of genomic and real-world data that will help develop personalized next-generation cancer treatments. Foundation Medicine In June of this year, Roche acquired Foundation Medicine for $2.4 billion. Headquartered in Cambridge, Massachusetts, FMI is a molecular information company specializing in cancer care. The company offers Comprehensive Genomic Profiling (CGP) to identify genetic mutations in patient cancers for use in targeted therapies, immunotherapy, and clinical trials. After the merger, Roche and Foundation Medicine will jointly use expertise in genomics and molecular information to enhance the development of personalized medicines and provide care for cancer patients. Second, the acquisition is dedicated to driving the ubiquity of Foundation Medicine's high-quality comprehensive genome analysis (CGP) testing and innovative data services to realize Roche's vision of personalized healthcare. Empowered medical institutions to provide accurate medical decision support Roche believes that data on patients and drugs has flowed in from many sources—in vivo diagnostics, lifestyle sensors, laboratories, electronic records, clinical trial data, genomic data, doctors, and patients themselves. Together, these data have the potential to drive better decisions and find the most effective treatment for patients. It can also be found that if the pharmaceutical companies only focus on the end of the pharmaceutical industry, they will be left behind, leaving the previous patient data, and in the increasingly severe research and development environment, it is impossible to develop new drugs. . The winner is the person who can master the entire data closed loop. Viewics In November 2017, Roche acquired Viewics, a US lab big data company. Viewics focuses on business analysis in the lab, capturing data from a variety of sources and extracting data to make faster data-driven decisions in the lab's operations. “The Viewics platform provides labs with powerful tools and analysis to help increase lab productivity,†said Christian Hebich, Head of Solution Integration and Services at Roche Diagnostics. “This is an improvement for our products. From stand-alone systems to integrated systems, providing total solutions for healthcare developers, providers and patients." GE healthCare In January 2018, Roche announced a joint development of a comprehensive diagnostic platform with GE HealthCare to improve the treatment of oncology and intensive care. Both parties will jointly develop software to drive faster and more accurate early decisions. Roche's role in this is to use his existing biomarker data, histopathology data, in vitro data from genomics data and sequencing data sequencing, and apply advanced analysis to in vivo data from GE medical imaging and monitoring equipment. Syapse Syapse provides the basis for decision making for precision medicine and focuses on cancer treatment. San Francisco-based Syapse provides a data-sharing network from doctors' centers in multiple healthcare systems. The system integrates anonymous electronic health records, laboratory reports and DNA sequencing data. Syapse and Roche will work together to develop new software and analytics solutions that provide healthcare providers with the tools and insights they need to achieve massive precision medicine. By combining Syapse software with Roche's oncology expertise, this collaboration will make precision medicine a reality for cancer patients and their healthcare providers. Syapse also offers solutions that match clinical trials based on a large amount of patient data. Accenture Accenture In December last year, Accenture announced a partnership with Roche to digitally improve the survival of cancer patients. Accelerate treatment and medical decision making for oncology treatment through data integration services. Accenture's dataset capabilities will enable Roche to integrate patient data between hospitals and Navify Tumor Board solutions to support clinicians in providing the best possible treatment decisions for patients. Accenture will provide digital data integration services for Roche's NAVIFY Tumor Board solution. The Navify Tumor Board solution is Roche's clinical workflow and decision support software that optimizes cancer patients' decisions in clinics, oncology committees, or multidisciplinary group meetings. The NAVIFY Tumor Board solution simplifies and standardizes the clinical oncology committee workflow process by aggregating relevant patient data from different IT systems into a single software solution, thereby facilitating effective teamwork, reducing errors, and giving the care team more Time to evaluate individual patient cases. Digitally empowering patients Personalized medicine is consumer-centric. Accenture's 2016 Patient Support Services survey, “The Increasing Opportunities for Pharmaceutical Companies in Patient Services,†shows that by 2018, 95% of pharmaceutical companies will invest in patient participation in technology. Patient services will become the standard for user support, not niche additions. mySugr Roche acquired the Austrian diabetes management platform mySugr in October 2017. The mySugr platform consists of applications and services, including diabetes guidance, treatment management, unlimited test strips, automated data tracking, and integration with other medical devices. Becoming the core of the latter's new, patient-centered diabetes digital health care service. Becoming the core of the latter's new, patient-centered diabetes digital health care service. Frank Suerman, CEO and co-founder of mySugr, said: "We started mySugr to solve our daily problems and simplify diabetes treatment through smartphones. So far, mySugr team has helped more than 1 million users manage their lives, with Roche's With diabetes expertise and a global network, mySugr will scale again. Senseonics&TypeZero Roche will work with Senseonics & TypeZero on implantable blood glucose meters. Eversense, the implantable continuous blood glucose monitoring system from Senseonics, has been approved by the FDA in June and will be available in the US. The promise of automated insulin delivery systems is the ability to maintain strict glycemic control automatically and sustainably while avoiding hypoglycemia. Tim Goodnow, president and CEO of Senseonics, said in a statement: "Through this partnership, we are closer to bringing this commitment to market and significantly improving the daily life challenges of people with diabetes. One step.†Eversense has been listed in Europe before, and Roche and Senseonics have already started a good European distribution cooperation. But in the US, Senseonics will distribute itself. Own APP Roche has quietly launched the Accu-Chek Connect app, a diabetes management app. The app provides multiple reporting options for people with diabetes to help them identify trends and patterns in blood glucose levels and allows them to share data with caregivers or medical teams via a networked online account, email or text message. It receives data from the Accu-Chek Aviva connected Bluetooth meter. As of June 27th, this app is available on both iOS and Android devices in the US. Use of this application must be guaranteed to be activated by a professional health care provider and set up relevant information. The APP is also a prescription drug use in FDA approved applications. In addition to insulin injections, the app also provides a user with the ability to record meals, including size, calories and carbohydrates. Users can choose to share food information with their own medical team through connected accounts. In addition to digital innovation, Roche has shown a lot of potential in becoming the first pharmaceutical company. In Roche's second largest market in China, Roche successfully completed the negotiation of national drug prices for four main products, and accelerated the approval of new drugs for cancer. The Roche Innovation Center of 863 million yuan is under construction in the Shanghai campus. Dr. Shi Wan, CEO of Roche Global, once said that China can become the largest market beyond the US and become Roche's next Genentech. Other innovations at Roche include the provision of patient platforms, patient education, and recruitment of clinical trial patients. Advance cancer treatment in emerging markets and countries, including the establishment of a health care system in the public health sector in the Middle East to advance breast cancer survival. In the past, they are all prologues. With the advent of the digital age, the pattern between pharmaceutical companies is being rewritten. It has been 120 years since Roche developed. Looking at the development of Roche, innovation is indeed the Roche gene. But more importantly, Roche is moving toward unmet needs every time, establishing market position with breakthrough innovation. The road to the future is not necessarily the one with the most people. Roche's most worthwhile place to learn is to be able to quickly grasp the direction of the industry's development and respond with timely and powerful actions. In innovation, we must not only develop the ability to explore the direction of the industry, but also forge the power that can lead the change. The second major feature of Roche's innovation is to hold the core key points and open up the value chain process. Roche's innovative layout is interlocking and there is no decentralized play. Solve the most basic data problems and solve barriers by means of mergers and acquisitions. Roche is willing to spend money, but Roche's most worth learning is always spending money on the blade. Once again, the sword took the slant, and it was the second time that the hand came. Raw Pumpkin Kernels,Raw Pumpkin Seed Kernels,Shelled Pumpkin Seeds,Raw Pumpkin Seeds Eaten Wuyuan county dafeng oil food co.,ltd , https://www.dafengfood.com.cn